<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="letter"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Crit Care Sci</journal-id><journal-id journal-id-type="iso-abbrev">Crit Care Sci</journal-id><journal-id journal-id-type="publisher-id">ccsci</journal-id><journal-title-group><journal-title>Critical Care Science</journal-title></journal-title-group><issn pub-type="epub">2965-2774</issn><publisher><publisher-name>Associa&#x000e7;&#x000e3;o de Medicina Intensiva Brasileira - AMIB</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC12094689</article-id><article-id pub-id-type="other">00602</article-id><article-id pub-id-type="doi">10.62675/2965-2774.20250164</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Letter</subject></subj-group></article-categories><title-group><article-title>Comparison between computer-guided and conventional paper-based insulin infusion protocols in the treatment of acute hyperglycemic syndromes: an observational study</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0006-4133-6987</contrib-id><name><surname>Mesquita</surname><given-names>Laura Andrade</given-names></name><role>All the authors had full access to the data</role><role>revised the manuscript and approved the final version of the manuscript</role><role>prepared the initial version of the manuscript and contributed to the study design</role><role>conception</role><role>data collection and statistical analysis</role><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9146-4606</contrib-id><name><surname>Toyoshima</surname><given-names>Marcos Tadashi Kakitani</given-names></name><role>All the authors had full access to the data</role><role>revised the manuscript and approved the final version of the manuscript</role><role>contributed to the English translation and review of the final version</role><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0007-2761-9937</contrib-id><name><surname>Silva</surname><given-names>Carolina Luz</given-names></name><role>All the authors had full access to the data</role><role>revised the manuscript and approved the final version of the manuscript</role><role>contributed to the English translation and review of the final version</role><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-1691-2058</contrib-id><name><surname>Feitosa</surname><given-names>Alina Coutinho Rodrigues</given-names></name><role>All the authors had full access to the data</role><role>revised the manuscript and approved the final version of the manuscript</role><role>prepared the initial version of the manuscript and contributed to the study design</role><role>conception</role><role>data collection and statistical analysis</role><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref></contrib></contrib-group><aff id="aff1">
<label>1</label>
<institution content-type="orgname">Escola Bahiana de Medicina e Sa&#x000fa;de P&#x000fa;blica</institution>
<addr-line>
<named-content content-type="city">Salvador</named-content>
<named-content content-type="state">BA</named-content>
</addr-line>
<country country="BR">Brazil</country>
<institution content-type="original">Escola Bahiana de Medicina e Sa&#x000fa;de P&#x000fa;blica - Salvador (BA), Brazil.</institution>
</aff><aff id="aff2">
<label>2</label>
<institution content-type="orgdiv2">Hospital das Cl&#x000ed;nicas</institution>
<institution content-type="orgdiv1">Faculdade de Medicina</institution>
<institution content-type="orgname">Universidade de S&#x000e3;o Paulo</institution>
<addr-line>
<named-content content-type="city">S&#x000e3;o Paulo</named-content>
<named-content content-type="state">SP</named-content>
</addr-line>
<country country="BR">Brazil</country>
<institution content-type="original">Instituto do C&#x000e2;ncer Oct&#x000e1;vio Frias de Oliveira, Hospital das Cl&#x000ed;nicas, Faculdade de Medicina, Universidade de S&#x000e3;o Paulo - S&#x000e3;o Paulo (SP), Brazil.</institution>
</aff><aff id="aff3">
<label>3</label>
<institution content-type="orgname">Hospital Santa Izabel</institution>
<addr-line>
<named-content content-type="city">Salvador</named-content>
<named-content content-type="state">BA</named-content>
</addr-line>
<country country="BR">Brazil</country>
<institution content-type="original">Hospital Santa Izabel - Salvador (BA), Brazil.</institution>
</aff><author-notes><corresp id="c01">
<label>Corresponding author</label>: Laura Andrade Mesquita. Escola Bahiana de Medicina e Sa&#x000fa;de P&#x000fa;blica. Avenida Dom Jo&#x000e3;o VI, 274 - Brotas. Zip code: 40285-001 - Salvador (BA), Brazil. E-mail: <email>laura.amesquita@outlook.com.br</email>
</corresp><fn fn-type="COI-statement"><p><bold>Conflicts of interest:</bold> None.</p></fn><fn fn-type="edited-by"><p><bold>Responsible editor:</bold> Viviane Cordeiro Veiga. <ext-link xlink:href="https://orcid.org/0000-0002-0287-3601" ext-link-type="uri">https://orcid.org/0000-0002-0287-3601</ext-link>
</p></fn></author-notes><pub-date pub-type="epub"><day>06</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>37</volume><elocation-id>e20250164</elocation-id><history><date date-type="received"><day>26</day><month>5</month><year>2024</year></date><date date-type="accepted"><day>16</day><month>10</month><year>2024</year></date></history><permissions><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY license (<ext-link xlink:href="https://creativecommons.org/licenses/by/4.0/" ext-link-type="uri">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><counts><fig-count count="1"/><table-count count="1"/><equation-count count="0"/><ref-count count="10"/></counts></article-meta></front><body><p>Acute hyperglycemic syndrome (AHS), including diabetic ketoacidosis (DKA) and a hyperosmolar hyperglycemic state (HHS), is a critical emergency requiring prompt and effective management. Intravenous insulin therapy is the cornerstone of treatment. Electronic glucose management systems (eGMSs) are increasingly used in treating AHS,<sup>(<xref rid="B1" ref-type="bibr">1</xref>)</sup>demonstrating positive outcomes such as the resolution of AHS<sup>(<xref rid="B2" ref-type="bibr">2</xref>,<xref rid="B3" ref-type="bibr">3</xref>)</sup>and a reduction in the incidence of hypoglycemia.<sup>(<xref rid="B2" ref-type="bibr">2</xref>,<xref rid="B4" ref-type="bibr">4</xref>,<xref rid="B5" ref-type="bibr">5</xref>)</sup> InsulinAPP-UTI&#x000ae;, a Brazilian eGMS, is available in Portuguese, English, and Spanish and was initially developed for managing hospital hyperglycemia in critical patients;<sup>(<xref rid="B6" ref-type="bibr">6</xref>,<xref rid="B7" ref-type="bibr">7</xref>)</sup>however, its potential benefits in managing AHS are worth exploring.</p><p>This retrospective cohort study compared the efficacy and safety of InsulinAPP-UTI&#x000ae; (eGMS group) with those of a conventional paper-based protocol (PP group) in managing AHS.</p><p>We included adult patients with AHS, as per the American Diabetes Association (ADA) criteria,<sup>(<xref rid="B8" ref-type="bibr">8</xref>)</sup> treated with intravenous insulin therapy. The InsulinAPP-UTI&#x000ae; was implemented in June 2020, allowing comparisons between the preimplementation (May 2019 - May 2020) and postimplementation (July 2020 - July 2021) periods. June 2020 was considered a transition period. The PP followed the ADA recommendations for insulin therapy.<sup>(<xref rid="B8" ref-type="bibr">8</xref>)</sup> InsulinAPP-UTI&#x000ae; insulin dose calculations are based on current blood glucose levels and their variation over time.<sup>(<xref rid="B7" ref-type="bibr">7</xref>)</sup> The study was approved by the Ethics Committee for National Research (CAAE: 59667622.0.0000.5520).</p><p>The primary outcome was the resolution of AHS, defined by normalization of blood glucose levels and resolution of acidosis or hyperosmolality.<sup>(<xref rid="B8" ref-type="bibr">8</xref>)</sup> Secondary outcomes included the length of hospital stay, mortality, time to resolution of AHS, number of patients with hypoglycemic events (&#x0003c; 70mg/dL), hypokalemia (&#x0003c; 3.3mEq/L), intensive care unit admission rate, and reintroduction of intravenous insulin after suspension. The frequency of blood tests was similar in both groups, including capillary blood glucose every one to two hours and monitoring of electrolytes (sodium and potassium) every two to four hours until the patient was stable.<sup>(<xref rid="B8" ref-type="bibr">8</xref>)</sup></p><p>Statistical analysis was performed via SPSS version 14.0 (Chicago, USA), with p values &#x0003c; 0.05 considered significant.</p><p>Among the 3,632 patients screened, 52 met the inclusion criteria: 16 in the PP group and 36 in the eGMS group (<xref rid="f01" ref-type="fig">Figure 1</xref>). Baseline characteristics, including age, sex, and body mass index, were similar between the groups. However, the eGMS group had a greater prevalence of type 2 diabetes (T2D; 93.1% <italic toggle="yes">versus</italic> 50.0%, p &#x0003c; 0.05). Only the eGMS group included patients with COVID-19. Corticosteroid use at hospital admission and the patient severity score (APACHE II) were similar in both groups.</p><p>
<fig position="float" id="f01"><label>Figure 1</label><caption><title>Patient selection process.</title><p>AHS - acute hyperglycemic syndrome. *Acute hyperglycemic syndrome criteria: diabetic ketoacidosis: glucose &#x0003e; 250mg/dL, metabolic acidosis, and positive ketonemia or hyperosmolar hyperglycemic state: glucose &#x0003e; 600mg/dL and seric osmolality &#x0003e; 320mOsm/kg.</p></caption><graphic xlink:href="2965-2774-ccsci-37-e20250164-gf01" position="float"/></fig>
</p><p>The eGMS group demonstrated 80.5% resolution of AHS, and the PP group demonstrated 68.7% resolution. However, the difference was not statistically significant. Similarly, no significant differences were observed in mortality, hypoglycemic events, or time to achieve AHS resolution (<xref rid="t1" ref-type="table">Table 1</xref>).</p><p>
<table-wrap position="float" id="t1"><label>Table 1</label><caption><title>Outcomes of patients with acute hyperglycemic syndrome treated with a paper-based protocol and an electronic glucose management system</title></caption><table frame="hsides" rules="groups"><colgroup width="20%" span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr><th align="left" rowspan="2" colspan="1">Variable</th><th style="font-weight:normal" rowspan="1" colspan="1">Paper-based protocol</th><th rowspan="1" colspan="1">eGMS</th><th rowspan="2" colspan="1">p value</th><th rowspan="2" colspan="1">OR (95%CI)</th></tr><tr><th rowspan="1" colspan="1">(n = 16)</th><th rowspan="1" colspan="1">(n = 36)</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">AHS resolution during hospitalization</td><td align="center" rowspan="1" colspan="1">11 (68.7)</td><td align="center" rowspan="1" colspan="1">29 (80.5)</td><td align="center" rowspan="1" colspan="1">0.478</td><td align="center" rowspan="1" colspan="1">0.53 (0.13 - 2.03)</td></tr><tr><td rowspan="1" colspan="1">Time to AHS resolution (hours)</td><td align="center" rowspan="1" colspan="1">25.5 (7.5 - 45.5)</td><td align="center" rowspan="1" colspan="1">27.8 (8.5 - 87.5)</td><td align="center" rowspan="1" colspan="1">0.261</td><td rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">Mortality</td><td align="center" rowspan="1" colspan="1">4 (25)</td><td align="center" rowspan="1" colspan="1">11 (30.5)</td><td align="center" rowspan="1" colspan="1">0.752</td><td align="center" rowspan="1" colspan="1">0.75 (0.19 - 2.8)</td></tr><tr><td rowspan="1" colspan="1">Incidence of hypoglycemia (&#x0003c; 70mg/dL)</td><td align="center" rowspan="1" colspan="1">10 (62.5)</td><td align="center" rowspan="1" colspan="1">21 (58.3)</td><td align="center" rowspan="1" colspan="1">0.777</td><td align="center" rowspan="1" colspan="1">1.19 (0.35 - 3.99)</td></tr><tr><td rowspan="1" colspan="1">Incidence of hypokalemia (&#x0003c; 3.3mEq/L)</td><td align="center" rowspan="1" colspan="1">6 (37.5)</td><td align="center" rowspan="1" colspan="1">11 (30.5)</td><td align="center" rowspan="1" colspan="1">0.622</td><td align="center" rowspan="1" colspan="1">1.36 (0.39 - 4.69)</td></tr><tr><td rowspan="1" colspan="1">ICU admission</td><td align="center" rowspan="1" colspan="1">15 (93.8)</td><td align="center" rowspan="1" colspan="1">26 (72.2)</td><td align="center" rowspan="1" colspan="1">0.140</td><td align="center" rowspan="1" colspan="1">5.76 (0.67 - 49.60)</td></tr><tr><td rowspan="1" colspan="1">Reintroduction of intravenous insulin after suspension</td><td align="center" rowspan="1" colspan="1">4 (25)</td><td align="center" rowspan="1" colspan="1">9 (25)</td><td align="center" rowspan="1" colspan="1">1.000</td><td align="center" rowspan="1" colspan="1">1.00 (0.25 - 3.89)</td></tr><tr><td rowspan="1" colspan="1">Corticosteroid usage in hospital admission</td><td align="center" rowspan="1" colspan="1">2 (12.5)</td><td align="center" rowspan="1" colspan="1">5 (13.9)</td><td align="center" rowspan="1" colspan="1">1.000</td><td align="center" rowspan="1" colspan="1">0.88 (0.15 - 5.13)</td></tr><tr><td rowspan="1" colspan="1">APACHE II score</td><td align="center" rowspan="1" colspan="1">13.5 (7.5 - 17.7)</td><td align="center" rowspan="1" colspan="1">15.0 (9.0 - 24.3)</td><td align="center" rowspan="1" colspan="1">0.290</td><td rowspan="1" colspan="1">&#x000a0;</td></tr></tbody></table><table-wrap-foot><fn id="TFN1"><p>eGMS - electronic glucose management system; OR - odds ratio; 95%CI - 95% confidence interval; AHS - acute hyperglycemic syndromes; ICU - intensive care unit; APACHE II - Acute Physiology and Chronic Health Evaluation II. p values &#x0003c; 0.05 were considered statistically significant. Data were presented in odds ratio and 95% confidence interval. Quantitative variables with nonnormal distribution were expressed as median and interquartile range, and Mann&#x02013;Whitney test was performed. Qualitative variables were described in absolute value and percentage, and Fisher&#x02019;s exact test was performed.</p></fn></table-wrap-foot></table-wrap>
</p><p>The COVID-19 pandemic has led to the use of high doses of corticosteroids, cytokine storms, poorer COVID-19 outcomes in preexisting diabetic mellitus patients and overload of the health care system,<sup>(<xref rid="B9" ref-type="bibr">9</xref>)</sup> which could also explain the high mortality in the eGMS group, despite greater AHS resolution.</p><p>The study&#x000b4;s limitations, including the retrospective and pre- and postintervention study design, small sample size and the impact of confounding factors such as the COVID-19 pandemic,<sup>(<xref rid="B9" ref-type="bibr">9</xref>, <xref rid="B10" ref-type="bibr">10</xref>)</sup>and the higher prevalence of T2D in the eGMS group, limit the generalizability of the findings. These factors may have introduced biases that influenced the outcomes.</p><p>While the study did not find significant differences between InsulinAPP-UTI&#x000ae; and the conventional paper protocol in resolving AHS, the results suggest that InsulinAPP-UTI&#x000ae; may offer comparable efficacy. Further prospective studies with larger, more homogeneous samples are necessary to validate the efficacy of InsulinAPP-UTI&#x000ae; in managing AHS and to assess its long-term impact on clinical outcomes.</p></body><back><ack><title>Acknowledgments</title><p>This project was approved by the Undergraduate Research Scholarship Program of <italic toggle="yes">Escola Bahiana de Medicina e Sa&#x000fa;de P&#x000fa;blica</italic>. There was no funding for the study presented.</p></ack><ref-list><title>REFERENCES</title><ref id="B1"><label>1</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Lam</surname><given-names>DW</given-names></name>
<name><surname>Feng</surname><given-names>Y</given-names></name>
<name><surname>Fleckman</surname><given-names>AM</given-names></name>
</person-group><part-title>Acute hyperglycemic syndromes: diabetic ketoacidosis and the hyperosmolar state</part-title><person-group person-group-type="editor">
<name><surname>Poretsky</surname><given-names>L</given-names></name>
<role>editor</role>
</person-group><source>Principles of Diabetes Mellitus</source><publisher-loc>Cham</publisher-loc><publisher-name>Springer International Publishing</publisher-name><year>2015</year><fpage>1</fpage><lpage>17</lpage></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ullal</surname><given-names>J</given-names></name>
<name><surname>McFarland</surname><given-names>R</given-names></name>
<name><surname>Bachand</surname><given-names>M</given-names></name>
<name><surname>Aloi</surname><given-names>J</given-names></name>
</person-group><article-title>Use of a computer-based insulin infusion algorithm to treat diabetic ketoacidosis in the Emergency Department</article-title><source>Diabetes Technol Ther</source><year>2016</year><volume>18</volume><issue>2</issue><fpage>100</fpage><lpage>103</lpage><pub-id pub-id-type="pmid">26783996</pub-id>
</element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Younis</surname><given-names>M</given-names></name>
<name><surname>Pham</surname><given-names>J</given-names></name>
<name><surname>Asad</surname><given-names>H</given-names></name>
<name><surname>Hamarshi</surname><given-names>MS</given-names></name>
</person-group><article-title>Computer-based versus paper-based insulin infusion algorithms in diabetic ketoacidosis</article-title><source>Curr Diabetes Rev</source><year>2020</year><volume>16</volume><issue>6</issue><fpage>628</fpage><lpage>634</lpage><pub-id pub-id-type="pmid">31538900</pub-id>
</element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Martinez</surname><given-names>HM</given-names></name>
<name><surname>Elwood</surname><given-names>K</given-names></name>
<name><surname>Werth</surname><given-names>C</given-names></name>
<name><surname>Sarangarm</surname><given-names>P</given-names></name>
</person-group><article-title>Evaluation of computer-based insulin infusion algorithm compared with a paper-based protocol in the treatment of diabetic ketoacidosis</article-title><source>J Pharm Technol</source><year>2023</year><volume>39</volume><issue>2</issue><fpage>82</fpage><lpage>87</lpage><pub-id pub-id-type="pmid">37051279</pub-id>
</element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Groysman</surname><given-names>AY</given-names></name>
<name><surname>Peragallo-Dittko</surname><given-names>V</given-names></name>
<name><surname>Islam</surname><given-names>S</given-names></name>
<name><surname>Klek</surname><given-names>S</given-names></name>
</person-group><article-title>Safety and efficacy of glucostabilizer in the management of diabetic ketoacidosis</article-title><source>Endocr Pract</source><year>2020</year><volume>26</volume><issue>6</issue><fpage>627</fpage><lpage>633</lpage><pub-id pub-id-type="pmid">31968186</pub-id>
</element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Souza</surname><given-names>AB</given-names></name>
<name><surname>Cukier</surname><given-names>P</given-names></name>
<name><surname>Toyoshima</surname><given-names>MT</given-names></name>
<name><surname>Oliveira</surname><given-names>E</given-names></name>
<name><surname>Di Rienzo</surname><given-names>RT</given-names></name>
<name><surname>Nery</surname><given-names>M</given-names></name>
</person-group><article-title>InsulinAPP-ICU: a safe and effective digital platform for continuous intravenous insulin therapy in intensive care unit</article-title><source>Rev Bras Ter Intensiva</source><year>2017</year><issue>Supl 1</issue><size units="pages">S208</size></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>C&#x000e2;mara de Souza</surname><given-names>AB</given-names></name>
<name><surname>Toyoshima</surname><given-names>MT</given-names></name>
<name><surname>Cukier</surname><given-names>P</given-names></name>
<name><surname>Lottenberg</surname><given-names>SA</given-names></name>
<name><surname>Bolta</surname><given-names>PM</given-names></name>
<name><surname>Lima</surname><given-names>EG</given-names></name>
<etal>et al</etal>
</person-group><article-title>Electronic glycemic management system improved glycemic control and reduced complications in patients with diabetes undergoing coronary artery bypass surgery: a randomized controlled trial</article-title><source>J Diabetes Sci Technol</source><year>2024</year><elocation-id>19322968241268352</elocation-id><pub-id pub-id-type="pmid">39096188</pub-id>
</element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kitabchi</surname><given-names>AE</given-names></name>
<name><surname>Umpierrez</surname><given-names>GE</given-names></name>
<name><surname>Miles</surname><given-names>JM</given-names></name>
<name><surname>Fisher</surname><given-names>JN</given-names></name>
</person-group><article-title>Hyperglycemic crises in adult patients with diabetes</article-title><source>Diabetes Care</source><year>2009</year><volume>32</volume><issue>7</issue><fpage>1335</fpage><lpage>1343</lpage><pub-id pub-id-type="pmid">19564476</pub-id>
</element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nabi</surname><given-names>AH</given-names></name>
<name><surname>Ebihara</surname><given-names>A</given-names></name>
<name><surname>Shekhar</surname><given-names>HU</given-names></name>
</person-group><article-title>Impacts of SARS-CoV-2 on diabetes mellitus: A pre and post pandemic evaluation</article-title><source>World J Virol</source><year>2023</year><volume>12</volume><issue>3</issue><fpage>151</fpage><lpage>171</lpage><pub-id pub-id-type="pmid">37396707</pub-id>
</element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Singh</surname><given-names>AK</given-names></name>
<name><surname>Khunti</surname><given-names>K</given-names></name>
</person-group><article-title>COVID-19 and Diabetes</article-title><source>Annu Rev Med</source><year>2022</year><volume>73</volume><issue>1</issue><fpage>129</fpage><lpage>147</lpage><pub-id pub-id-type="pmid">34379444</pub-id>
</element-citation></ref></ref-list></back></article>